Goldman Sachs
IMUX icon

Goldman Sachs’s Immunic IMUX Stock Holding History

Goldman Sachs’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-250
Closed -$404K – 7239
2015
Q3 		$404K Buy
+250
New +$1.25M ﹤0.01% 5348

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Goldman Sachs's IMUX Position: Q2 2026 in Review

Goldman Sachs sold out of Immunic (IMUX) in Q2 2026, closing a stake of 14,977 shares — an estimated $166K sold.

Goldman Sachs first reported a position in IMUX in Q2 2014 and held it in 31 quarters. The position peaked at $2.78M in Q1 2022. 56 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Goldman Sachs reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 14,977 Immunic shares in Q2 2026, an estimated $166K.
  • Goldman Sachs first reported a position in Immunic in Q2 2014 and held it in 31 quarters.
  • Goldman Sachs's Immunic position peaked at $2.78M in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.